Virpax Pharmaceuticals Statistics
Share Statistics
Virpax Pharmaceuticals has 8.09M shares outstanding. The number of shares has increased by -58.28% in one year.
| Shares Outstanding | 8.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 78.27% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 7.79M |
| Failed to Deliver (FTD) Shares | 31.86K |
| FTD / Avg. Volume | 0.98% |
Short Selling Information
The latest short interest is 350.86K, so 4.34% of the outstanding shares have been sold short.
| Short Interest | 350.86K |
| Short % of Shares Out | 4.34% |
| Short % of Float | 4.62% |
| Short Ratio (days to cover) | 1.04 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -0.66.
| PE Ratio | -0.25 |
| Forward PE | -0.66 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.94 |
| P/FCF Ratio | -0.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Virpax Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.
| Current Ratio | 1.25 |
| Quick Ratio | 1.25 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -7.85% and return on capital (ROIC) is -811.13%.
| Return on Equity (ROE) | -7.85% |
| Return on Assets (ROA) | -1.58% |
| Return on Capital (ROIC) | -811.13% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.17M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -89.54% in the last 52 weeks. The beta is 1.09, so Virpax Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -89.54% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 40.43 |
| Average Volume (20 Days) | 3.26M |
Income Statement
In the last 12 months, Virpax Pharmaceuticals had revenue of $0 and earned -$15.19M in profits. Earnings per share was $-12.97.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -15.69M |
| Net Income | -15.19M |
| EBITDA | -15.19M |
| EBIT | - |
| Earnings Per Share (EPS) | -12.97 |
Balance Sheet
The company has $9.14M in cash and $0 in debt, giving a net cash position of $9.14M.
| Cash & Cash Equivalents | 9.14M |
| Total Debt | 0 |
| Net Cash | 9.14M |
| Retained Earnings | -59.54M |
| Total Assets | 304.16K |
| Working Capital | -2.05M |
Cash Flow
In the last 12 months, operating cash flow was -$9.85M and capital expenditures $0, giving a free cash flow of -$9.85M.
| Operating Cash Flow | -9.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.85M |
| FCF Per Share | -8.41 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
VRPX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3163.41% |
| FCF Yield | -297.89% |
Analyst Forecast
The average price target for VRPX is $3, which is 631.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | 631.7% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 1, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Mar 1, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -511.2 |
| Piotroski F-Score | 0 |